Silence Therapeutics Files 2024 Annual Report Amendment
Ticker: SLNCF · Form: 10-K/A · Filed: Apr 30, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 10-K/A |
| Filed Date | Apr 30, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, sec-filing
TL;DR
Silence Therapeutics amended its 2024 10-K, filed April 30, 2025. Check for updates.
AI Summary
Silence Therapeutics plc filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, submitted on April 30, 2025, provides updated information regarding the company's financial performance and business operations. The company is incorporated in England and Wales and its principal executive offices are located in London.
Why It Matters
This amendment provides updated disclosures for investors regarding Silence Therapeutics' financial health and operational status as of December 31, 2024.
Risk Assessment
Risk Level: low — This is a routine amendment to an annual report, not indicating new material adverse events.
Key Numbers
- 2024 — Fiscal Year End (The annual report covers the period ending December 31, 2024.)
- April 30, 2025 — Filing Date (This amendment was filed on this date.)
Key Players & Entities
- Silence Therapeutics plc (company) — Registrant
- 2024 (date) — Fiscal year end
- April 30, 2025 (date) — Filing date
- England and Wales (jurisdiction) — Place of incorporation
- London (location) — Principal executive offices
FAQ
What is the purpose of this 10-K/A filing?
This 10-K/A filing is an amendment to Silence Therapeutics plc's annual report for the fiscal year ended December 31, 2024.
When was the original 10-K filed or when is this amendment being filed?
The amendment (10-K/A) was filed on April 30, 2025, and it pertains to the fiscal year ended December 31, 2024.
Where is Silence Therapeutics plc incorporated?
Silence Therapeutics plc is incorporated in England and Wales.
What is the address of Silence Therapeutics plc's principal executive offices?
The principal executive offices are located at 72 Hammersmith Road, London, United Kingdom, W14 8TH.
What is the SEC file number for Silence Therapeutics plc?
The SEC file number for Silence Therapeutics plc is 001-39487.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 30, 2025 regarding Silence Therapeutics plc (SLNCF).